[1] | Chey, W., Drossman, D., Johanson, J., Scott, C., Panas, R., & Ueno, R. (2011). Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, [publication pending]. |
[2] | Myshko, D. (2011). Developing a true strategic partnership. Featured Experts: V. Aurentz, T. Dietlin, M Goldberg, R. Panas, J. Remnant, M. Roseman, A. Smink, C. Terry, and G. Wright. PharmaVOICE, 11(2):10-17. |
[3] | Myshko, D. (2009). Global development. Featured Experts: T Bocanegra, M Goldberg, R. Keohand, J. Garaud, R. Panas, and B. Thompson. PharmaVOICE, 9(3):36-41. |
[4] | Drossman, D., Chey, W., Johanson, J., Fass, R., Scott, C., Panas, R., & Ueno, R. (2009). Lubiprostone in patients with constipation-associated irritable bowel syndrome: Results of two randomized, placebo-controlled trials. Alimentary Pharmacology and Therapeutics, 29(3):329-341. |
[5] | Panas, R. (2008). Differences Among Subjects in a Pharmaceutical Clinical Trial as Determined by Recruitment Method. Berkley, CA: The Berkeley Electronic Press. |
[6] | Johanson, J., Drossman, D., Panas, R., Wahle, A., & Ueno, R. (2008). Phase 2 trial of lubiprostone for irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 27(8):685-696. |
[7] | Panas, R. (1991). AIDS Counseling and Testing: The Concepts. Pittsburgh, PA: Allegheny County Health Department. |